Raymond James downgraded Inozyme (INZY) to Market Perform from Outperform after BioMarin (BMRN) agreed to acquire Inozyme for $4.00 per share in cash.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme downgraded to Hold from Buy at Needham
- Inozyme downgraded to Equal Weight from Overweight at Wells Fargo
- Inozyme Pharma’s INZ-701 Shows Promising Results in ENERGY-3 Study, Highlighting Investment Potential
- BioMarin says Inozyme deal to strengthen enzyme therapies portfolio
- Inozyme downgraded to Neutral from Outperform at Wedbush